drugset / Trial / NCT01837108

Eplerenone and Extracellular Adenosine Formation

NCT01837108

Phase 4 Completed 14 enrolled Radboud University Medical Center
RandomizedCrossoverQuadruple-blindBasic science

Summary

Various studies have reported cardioprotective effects of mineralocorticoid receptor (MR) antagonists in the setting of an acute myocardial infarction. In a recent animal study, the protective effect of MR antagonists on infarct size was completely abolished in CD73 knock-out and adenosine A2b receptor knock-out mice, and by co-administration of adenosine receptor antagonists in rats. These findings suggest that extracellular formation of adenosine is crucial for this protective effect and that MR antagonists stimulate extracellular adenosine formation by the enzyme CD73. To investigate whether eplerenone promotes adenosine receptor stimulation by activating CD73, the investigators will measure forearm blood flow in response to various dosages of dipyridamole with the use of plethysmography. Dipyridamole increases the extracellular endogenous adenosine concentration by inhibition of the ENT transporter and induces local vasodilation. Therefore, the vasodilator effect of dipyridamole accurately reflects extracellular adenosine formation by the CD73 enzyme.

Timeline

Start
2013-04
Primary completion
2013-12
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Eplerenone Unknown 50 mg

Indications

No indication recorded.